The lncRNA prostate androgen-regulated transcript 1 (PART-1) promotes non-small cell lung cancer progression by regulating the miR-204-3p/IGFBP-2 pathway
Li Kenfen, Zhang Yanping, Wang Yunfeng and 3 more
Journal of Laboratory Medicine · 2023
doi:10.1515/labmed-2022-0082 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Objectives Lung cancer is a common malignant tumour of the lung and the leading cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung cancers, and 40% of NSCLCs have spread beyond the lungs by the time they are diagnosed. The long noncoding RNA (lncRNA) prostate androgen-regulated transcript 1 (PART-1) has been reported to promote the development of several cancers. Methods In the current study, we investigated the role of PART-1 in the proliferation, invasion, and migration of NSCLC. Results The expression levels of the PART-1 gene were higher in NSCLC cell lines, including A549, H1229, H1650, H1975, and PC9, than in human bronchial epithelia (HBE) cell lines. Knocking down PART-1 inhibited the proliferation, invasion, and migration of A549 cells and decreased tumour proliferation in nude mice. We confirmed that PART-1 targeted miR-204-3p directly and that miR-204-3p targeted insulin-like growth factor binding protein 2 (IGFBP-2) directly. Furthermore, we discovered that PART-1 impacts NSCLC progression by regulating the miR-204-3p-targeted IGFBP-2 pathway. Conclusions The lncRNA PART-1 might be a target for treating NSCLC and an early marker in the diagnosis of early lung cancer.
Abstract licence: CC BY
References39
- 6.
- 13.
- 19.
36 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.